(C. J. Kirk, unpublished work) .
Although the glycogenolytic responses of rat hepatocytes to vasopressin, angiotensin and a-adrenergic stimuli all seem to involve Caz+, the phosphatidylinositol response appears to occur independently of hormone-induced changes in cytosolic Ca2+ concentration. Two observations lead to this conclusion: (a) phosphatidylinositol breakdown and labelling are both resistant, at least partially, to cellular Ca2+ deprivation ; (b) admission of CaZ+ into hepatocytes with the ionophore A23 187 brings about neither of these responses (Kirk et af., 1978; Billah & Michell, 1978 . Kirk et al. (1979) used seven vasopressin-like peptides to investigate the ligand selectivity of the receptors involved in stimulation of hepatic phosphorylase and phosphatidylinositol turnover, with several important results. For each ligand, the dose-response curves describing the two effects were broadly parallel, but the phosphatidylinositol response routinely required a 5-20-fold greater concentration of each peptide than did stimulation of phosphorylase activity. As a consequence of this relationship, a small and relatively constant stimulation of phosphatidylinositol labelling was always apparent over the range of ligand concentrations that effectively stimulated phosphorylase activity. These observations are compatible with the view that the same population of vasopressin receptors is responsible for evoking both responses. They also suggest that hepatocytes possess a substantial 'reserve' of vasopressin receptors, at least so far as stimulation of phosphorylase is concerned, and that phosphatidylinositol breakdown may be intimately involved in the coupling of vasopressin receptors to Ca2+ mobilization in the cytosol.
The ligand selectivity of this population of receptors appeared markedly different from that displayed by the vasopressin receptors of the renal tubule (Table 1) . A particularly clear distinction between these two activities was seen with [I-deaminocysteine, 2-phenylalanine, 7-(3,4-didehydroproline), 8-argininelvasopressin (Kirk et al., 1979; Billah & Michell, 1979) . This analogue, which was synthesized by Smith & Walter (1978), acts extremely effectively upon the renal vasopressin receptors; it has the highest antidiuretic potency yet recorded. By contrast, it was a very poor agonist at the hepatic vasopressin receptors that control glycogenolysis and phosphatidylinositol breakdown (Kirk et al., 1979; Billah & Michell, 1979 ; see Table 1 ).
It has long been known that the relative potencies of various vasopressin derivatives differ, depending on whether one assays their antidiuretic or vasopressor effects. In addition, it has been clear that the antidiuretic effects correlate with effects upon renal adenylate cyclase, whilst the vasopressor effects approximately parallel the abilities of ligands to cause contraction of vascular smooth muscle. In general, the hepatic effects of vasopressin tend to fall into the latter category [Kirk et al. (1979) ; Table 11 . The studies on isolated hepatocytes and upon renal membranes by Hechter et al. (1978) suggest that there are at least two distinct populations of vasopressin receptors, and that they are functionally equivalent to previously known pairs of receptors responsive to single ligands. In the hepatocyte, vasopressin interacts with a receptor population which controls the cells by bringing about a rise in cytosolic CaZ+ concentration (Blackmore et al., 1978) and which also stimulates phosphatidylinositol breakdown. Functionally, this receptor is analogous to the a,-adrenergic receptor and to the HI-histamine receptor (Jafferji & Michell, 1976) , and it would therefore seem appropriate to name it the V,-vasopressin receptor. By contrast, renal vasopressin receptors control adenylate cyclase and are therefore functionally analogous to Badrenergic receptors and H,-histamine receptors; we would propose that these should be named Vz-vasopressin receptors. One would then expect that many systemic effects of vasopressin will be dominated by one or other of these receptor types (e.g. the V1-receptor in vasopressor activity and in mobilization of liver glycogen, and the Vz-receptor in antidiuretic effects), but that many responses of the whole animal will arise by an interplay between the effects of vasopressin upon receptors of different types. An obvious prediction arising from this idea (Michell et al., 1977) , but one that has not yet been tested, is that whenever vasopressin stimulates contraction in smooth muscles, then it should also stimulate the metabolism of phosphatidylinositol.
At present, the most widely considered possible function for ligand-stimulated phosphatidylinositol breakdown is as a coupling reaction in the mobilization of Ca2+ that is brought about by stimulation of many membrane receptors (Michell, 1975 (Michell, , 1979a Fain, 1978; Berridge & Fain, 1979; Fain & Berridge, 1979; Bicknell et al., 1979; Young et al., 1979; Cockcroft & Gomperts, 1979; Putney, 1979) . It is usually considered in this model that the initial phosphatidylinositol breakdown occurs by the action of a specific phosphodiesterase located at the plasma membrane (Michell et al., 1977; Berridge & Fain, 1979) . However, there are also at least three alternative views currently being expressed. (1978) have discovered a lysosomal phosphatidylinositol phosphodiesterase which differs from the cytosol and membrane-bound activities by having an acid pH optimum and by not producing inositol 1,2-cyclic phosphate as one of its products. They consider that this may be the key enzyme in stimulated phosphatidylinositol metabolism. (3) now considers that phosphatidylinositol breakdown occurs by reversal of its biosynthesis and has preliminary evidence, at least for the exocrine pancreas, that acetylcholine-stimulated phosphatidylinositol breakdown may occur at the endoplasmic reticulum (Harris & Hokin-Neaverson, 1977) . There are already strong lines of evidence that argue against some aspects of alternatives 2 and 3, always provided that one is correct in making the unifying assumption that the fundamental mechanism of the phosphatidylinositol response is always the same, irrespective of the tissue/stimulus combination under study. Alternative 3 neither predicts the observed turnover of the phosphate zroup of phosphatidylinositol, a feature that has been a hallmark of all phosphatidylinositol responses for at least 25 years, nor does it explain the detection of inositol phosphates, rather than free inositol, as products of stimulated phosphatidylinositol breakdown (Clements & Rhoten, 1976; Fain & Berridge, 1979) . Alternative 2 predicts that inositol 1-phosphate will be the sole water-soluble product of stimulated phosphatidylinositol breakdown ; thus it provides no explanation for the appearance amongst these products of inositol 1 ,2-cyclic phosphate. Finally, all of these three alternative models propose primary sites of phosphatidylinositol breakdown which are remote from the activation of hormone receptors at the plasma membrane. At present, the only 'second messenger' that appears common to the cellular responses to all stimuli that provoke phosphatidylinositol breakdown is the CaZ+ ion, and this does not seem to be responsible for control of phosphatidylinositol breakdown.
In the past, the best systems for the study of the phosphatidylinositol response have often been tissues for which pharmacological knowledge was very detailed, but whose biochemistry was less amenable to study. It now appears, at least for many forms of biochemical study, that isolated hepatocytes should become a favoured system. They are easily prepared in substantial quantities (either prelabelled or unlabelled), they can readily be subjected to subcellular fractionation, and'they are relatively free of the large quantities of specialized functional proteins that characterize secretory and contractile tissues. This experimental amenability may help to answer some of the questions that have seemed intractable when studying other tissues.
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